Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Duel(ling) precursors in thymic Treg development.

Maltzman JS.

Sci Immunol. 2019 Jun 7;4(36). pii: eaax9509. doi: 10.1126/sciimmunol.aax9509.

PMID:
31175179
2.

Single cell immune profiling in transplantation research.

Higdon LE, Schaffert S, Khatri P, Maltzman JS.

Am J Transplant. 2019 May;19(5):1278-1287. doi: 10.1111/ajt.15316. Epub 2019 Mar 20. Review.

PMID:
30768832
3.

Optimization of single-cell plate sorting for high throughput sequencing applications.

Higdon LE, Cain CJ, Colden MA, Maltzman JS.

J Immunol Methods. 2019 Mar;466:17-23. doi: 10.1016/j.jim.2018.12.006. Epub 2018 Dec 24.

PMID:
30590019
4.

Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study.

Shah MA, Starodub A, Sharma S, Berlin J, Patel M, Wainberg ZA, Chaves J, Gordon M, Windsor K, Brachmann CB, Huang X, Vosganian G, Maltzman JD, Smith V, Silverman JA, Lenz HJ, Bendell JC.

Clin Cancer Res. 2018 Aug 15;24(16):3829-3837. doi: 10.1158/1078-0432.CCR-17-2469. Epub 2018 Apr 24.

PMID:
29691300
5.

Inflammatory macrophage-associated 3-gene signature predicts subclinical allograft injury and graft survival.

Azad TD, Donato M, Heylen L, Liu AB, Shen-Orr SS, Sweeney TE, Maltzman JS, Naesens M, Khatri P.

JCI Insight. 2018 Jan 25;3(2). pii: 95659. doi: 10.1172/jci.insight.95659. eCollection 2018 Jan 25.

6.

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.

Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S.

Lancet Haematol. 2018 Feb;5(2):e73-e81. doi: 10.1016/S2352-3026(17)30237-5. Epub 2017 Dec 20.

PMID:
29275119
7.

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.

Pardanani A, Gotlib J, Roberts AW, Wadleigh M, Sirhan S, Kawashima J, Maltzman JA, Shao L, Gupta V, Tefferi A.

Leukemia. 2018 Apr;32(4):1035-1038. doi: 10.1038/leu.2017.330. Epub 2017 Nov 16. No abstract available.

PMID:
29263442
8.

Expanding the Toolkit for the Study of Allospecific B and T Cell Responses.

Higdon LE, Maltzman JS.

Transplantation. 2017 Nov;101(11):2661-2662. doi: 10.1097/TP.0000000000001880. No abstract available.

9.

The Relative Bioavailability, Food Effect, and Drug Interaction With Omeprazole of Momelotinib Tablet Formulation in Healthy Subjects.

Xin Y, Shao L, Maltzman J, Stefanidis D, Hemenway J, Tarnowski T, Deng W, Silverman JA.

Clin Pharmacol Drug Dev. 2018 Mar;7(3):277-286. doi: 10.1002/cpdd.397. Epub 2017 Oct 11.

PMID:
29024542
10.

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.

Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J.

J Clin Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20.

11.

The outstanding questions in transplantation: It's about time….

Azzi J, Raimondi G, Mas V, Riella LV, Elfadawy N, Safa K, Wojciechowski D, Kanak M, Nog R, Maltzman JS, Ford ML, Pober JS, Luo XR, Rothstein D, Miller ML, Matthews D, Burlingham W, Levings M, Heeger P, Higdon L, Gill J, Gill RG, Alegre ML.

Am J Transplant. 2018 Jan;18(1):271-272. doi: 10.1111/ajt.14450. Epub 2017 Sep 2. No abstract available.

12.

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.

Verstovsek S, Courby S, Griesshammer M, Mesa RA, Brachmann CB, Kawashima J, Maltzman JD, Shao L, Xin Y, Huang D, Bajel A.

Leuk Res. 2017 Sep;60:11-17. doi: 10.1016/j.leukres.2017.05.002. Epub 2017 May 30.

13.

A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.

Verstovsek S, Savona MR, Mesa RA, Dong H, Maltzman JD, Sharma S, Silverman J, Oh ST, Gotlib J.

Br J Haematol. 2017 Mar;176(6):939-949. doi: 10.1111/bjh.14501. Epub 2017 Feb 21.

PMID:
28220932
14.

Cytomegalovirus-Responsive CD8+ T Cells Expand After Solid Organ Transplantation in the Absence of CMV Disease.

Higdon LE, Trofe-Clark J, Liu S, Margulies KB, Sahoo MK, Blumberg E, Pinsky BA, Maltzman JS.

Am J Transplant. 2017 Aug;17(8):2045-2054. doi: 10.1111/ajt.14227. Epub 2017 Mar 13.

15.

Virtual Global Transplant Laboratory Standard Operating Procedures for Blood Collection, PBMC Isolation, and Storage.

Higdon LE, Lee K, Tang Q, Maltzman JS.

Transplant Direct. 2016 Aug 18;2(9):e101. eCollection 2016 Sep.

16.

Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection.

Gupta A, Hussein Z, Hassan R, Wustner J, Maltzman JD, Wallin BA.

Cancer Chemother Pharmacol. 2016 Apr;77(4):733-43. doi: 10.1007/s00280-016-2984-z. Epub 2016 Feb 22.

PMID:
26898299
17.

HA-ving lymphatics improves lung transplantation.

Maltzman JS, Reed HO, Kahn ML.

J Clin Invest. 2015 Nov 2;125(11):3999-4001. doi: 10.1172/JCI84549. Epub 2015 Oct 20.

18.

Do Mice Need an Order of Fries to Be Relevant for Transplant Studies?

Sawinski D, Maltzman JS.

Am J Transplant. 2015 Sep;15(9):2283-4. doi: 10.1111/ajt.13348. Epub 2015 Jun 16. No abstract available.

19.

Differentially expressed gene transcripts using RNA sequencing from the blood of immunosuppressed kidney allograft recipients.

Dorr C, Wu B, Guan W, Muthusamy A, Sanghavi K, Schladt DP, Maltzman JS, Scherer SE, Brott MJ, Matas AJ, Jacobson PA, Oetting WS, Israni AK.

PLoS One. 2015 May 6;10(5):e0125045. doi: 10.1371/journal.pone.0125045. eCollection 2015.

20.

Correction: Folate receptor-α (FOLR1) expression and function in triple negative tumors.

Necela BM, Crozier JA, Andorfer CA, Lewis-Tuffin L, Kachergus JM, Geiger XJ, Kalari KR, Serie DJ, Sun Z, Moreno-Aspitia A, O'Shannessy DJ, Maltzman JD, McCullough AE, Pockaj BA, Cunliffe HE, Ballman KV, Thompson EA, Perez EA.

PLoS One. 2015 Apr 30;10(4):e0127133. doi: 10.1371/journal.pone.0127133. eCollection 2015. No abstract available.

21.

Regulatory T cells require TCR signaling for their suppressive function.

Schmidt AM, Lu W, Sindhava VJ, Huang Y, Burkhardt JK, Yang E, Riese MJ, Maltzman JS, Jordan MS, Kambayashi T.

J Immunol. 2015 May 1;194(9):4362-70. doi: 10.4049/jimmunol.1402384. Epub 2015 Mar 27.

22.

Folate receptor-α (FOLR1) expression and function in triple negative tumors.

Necela BM, Crozier JA, Andorfer CA, Lewis-Tuffin L, Kachergus JM, Geiger XJ, Kalari KR, Serie DJ, Sun Z, Moreno-Aspitia A, O'Shannessy DJ, Maltzman JD, McCullough AE, Pockaj BA, Cunliffe HE, Ballman KV, Thompson EA, Perez EA.

PLoS One. 2015 Mar 27;10(3):e0122209. doi: 10.1371/journal.pone.0122209. eCollection 2015. Erratum in: PLoS One. 2015;10(4):e0127133. Aspita, Alvaro Moreno [corrected to Moreno-Aspitia, Alvaro].

23.

Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.

Lindenberg L, Thomas A, Adler S, Mena E, Kurdziel K, Maltzman J, Wallin B, Hoffman K, Pastan I, Paik CH, Choyke P, Hassan R.

Oncotarget. 2015 Feb 28;6(6):4496-504.

24.

Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.

Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA.

Clin Cancer Res. 2014 Dec 1;20(23):5927-36. doi: 10.1158/1078-0432.CCR-14-0804. Epub 2014 Sep 17.

25.

Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patients.

Christoph DC, Reyna-Asuncion B, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, Gauler TC, Wohlschlaeger J, Schuler M, Eberhardt WE, Hirsch FR.

Clin Lung Cancer. 2014 Sep;15(5):320-30.e1-3. doi: 10.1016/j.cllc.2014.05.002. Epub 2014 Jun 3.

PMID:
24993594
26.

AST Cutting Edge of Transplantation 2013 Meeting Report: a comprehensive look at B cells and antibodies in transplantation.

Mengel M, Chong A, Rothstein DM, Zorn E, Maltzman JS.

Am J Transplant. 2014 Mar;14(3):524-30. doi: 10.1111/ajt.12593. Epub 2014 Jan 24.

27.

T-cell costimulatory blockade in organ transplantation.

Maltzman JS, Turka LA.

Cold Spring Harb Perspect Med. 2013 Dec 1;3(12):a015537. doi: 10.1101/cshperspect.a015537. Review.

28.

Farletuzumab in lung cancer.

Thomas A, Maltzman J, Hassan R.

Lung Cancer. 2013 Apr;80(1):15-8. doi: 10.1016/j.lungcan.2012.12.021. Epub 2013 Jan 26. Review.

29.

An obligate cell-intrinsic function for CD28 in Tregs.

Zhang R, Huynh A, Whitcher G, Chang J, Maltzman JS, Turka LA.

J Clin Invest. 2013 Feb;123(2):580-93. doi: 10.1172/JCI65013. Epub 2013 Jan 2.

30.

Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.

Christoph DC, Asuncion BR, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, Wynes MW, Gauler TC, Wohlschlaeger J, Hoiczyk M, Schuler M, Eberhardt WE, Hirsch FR.

J Thorac Oncol. 2013 Jan;8(1):19-30. doi: 10.1097/JTO.0b013e31827628ff.

31.

Homeostatic division is not necessary for antigen-specific CD4+ memory T cell persistence.

Corbo-Rodgers E, Wiehagen KR, Staub ES, Maltzman JS.

J Immunol. 2012 Oct 1;189(7):3378-85. Epub 2012 Sep 5.

32.

Costimulation blockade-a double-edged sword?

Maltzman JS.

Am J Transplant. 2012 Sep;12(9):2269-70. doi: 10.1111/j.1600-6143.2012.04185.x. No abstract available.

33.

Foxp4 is dispensable for T cell development, but required for robust recall responses.

Wiehagen KR, Corbo-Rodgers E, Li S, Staub ES, Hunter CA, Morrisey EE, Maltzman JS.

PLoS One. 2012;7(8):e42273. doi: 10.1371/journal.pone.0042273. Epub 2012 Aug 13.

34.

Leukocyte: tempus fugit vel carpe diem.

Maltzman JS, Bromberg JS.

Am J Transplant. 2012 Jul;12(7):1665. doi: 10.1111/j.1600-6143.2012.04187.x. No abstract available.

35.

Site-specific accumulation of recently activated CD4+ Foxp3+ regulatory T cells following adoptive transfer.

Lieberman SM, Kim JS, Corbo-Rodgers E, Kambayashi T, Maltzman JS, Behrens EM, Turka LA.

Eur J Immunol. 2012 Jun;42(6):1429-35. doi: 10.1002/eji.201142286.

36.

Cutting edge: IL-2 signals determine the degree of TCR signaling necessary to support regulatory T cell proliferation in vivo.

Zou T, Satake A, Corbo-Rodgers E, Schmidt AM, Farrar MA, Maltzman JS, Kambayashi T.

J Immunol. 2012 Jul 1;189(1):28-32. doi: 10.4049/jimmunol.1200507. Epub 2012 May 23.

37.

Oral ivermectin as an unexpected initiator of CreT2-mediated deletion in T cells.

Corbo-Rodgers E, Staub ES, Zou T, Smith A, Kambayashi T, Maltzman JS.

Nat Immunol. 2012 Feb 16;13(3):197-8. doi: 10.1038/ni.2232. No abstract available.

38.

Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease.

O'Shannessy DJ, Somers EB, Maltzman J, Smale R, Fu YS.

Springerplus. 2012 Sep 28;1:22. doi: 10.1186/2193-1801-1-22. eCollection 2012.

39.

Adoptive Treg therapy: closer to the clinic.

Maltzman JS.

Am J Transplant. 2011 Dec;11(12):2545. doi: 10.1111/j.1600-6143.2011.03884.x. No abstract available.

40.

Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib.

Sherrill B, Sherif B, Amonkar MM, Maltzman J, O'Rourke L, Johnston S.

Curr Med Res Opin. 2011 Dec;27(12):2245-52. doi: 10.1185/03007995.2011.621209. Epub 2011 Oct 12.

PMID:
21992075
41.

T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse.

Moran AE, Holzapfel KL, Xing Y, Cunningham NR, Maltzman JS, Punt J, Hogquist KA.

J Exp Med. 2011 Jun 6;208(6):1279-89. doi: 10.1084/jem.20110308. Epub 2011 May 23.

42.

Probucol ameliorates renal and metabolic sequelae of primary CoQ deficiency in Pdss2 mutant mice.

Falk MJ, Polyak E, Zhang Z, Peng M, King R, Maltzman JS, Okwuego E, Horyn O, Nakamaru-Ogiso E, Ostrovsky J, Xie LX, Chen JY, Marbois B, Nissim I, Clarke CF, Gasser DL.

EMBO Mol Med. 2011 Jul;3(7):410-27. doi: 10.1002/emmm.201100149. Epub 2011 Jun 8.

43.

Conditional deletion of SLP-76 in mature T cells abrogates peripheral immune responses.

Wu GF, Corbo E, Schmidt M, Smith-Garvin JE, Riese MJ, Jordan MS, Laufer TM, Brown EJ, Maltzman JS.

Eur J Immunol. 2011 Jul;41(7):2064-73. doi: 10.1002/eji.201040809. Epub 2011 Jun 7.

44.

Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.

Lipton A, Leitzel K, Ali SM, Carney W, Platek G, Steplewski K, Westlund R, Gagnon R, Martin AM, Maltzman J.

Cancer. 2011 Nov 1;117(21):5013-20. doi: 10.1002/cncr.26101. Epub 2011 Mar 31.

45.

Antiviral memory CD8 T-cell differentiation, maintenance, and secondary expansion occur independently of MyD88.

Rahman AH, Zhang R, Blosser CD, Hou B, Defranco AL, Maltzman JS, Wherry EJ, Turka LA.

Blood. 2011 Mar 17;117(11):3123-30. doi: 10.1182/blood-2010-11-318485. Epub 2011 Jan 13.

46.

Loss of tonic T-cell receptor signals alters the generation but not the persistence of CD8+ memory T cells.

Wiehagen KR, Corbo E, Schmidt M, Shin H, Wherry EJ, Maltzman JS.

Blood. 2010 Dec 16;116(25):5560-70. doi: 10.1182/blood-2010-06-292458. Epub 2010 Sep 30.

47.

T-cell receptor signals direct the composition and function of the memory CD8+ T-cell pool.

Smith-Garvin JE, Burns JC, Gohil M, Zou T, Kim JS, Maltzman JS, Wherry EJ, Koretzky GA, Jordan MS.

Blood. 2010 Dec 16;116(25):5548-59. doi: 10.1182/blood-2010-06-292748. Epub 2010 Sep 16.

48.

Ezrin is highly expressed in early thymocytes, but dispensable for T cell development in mice.

Shaffer MH, Huang Y, Corbo E, Wu GF, Velez M, Choi JK, Saotome I, Cannon JL, McClatchey AI, Sperling AI, Maltzman JS, Oliver PM, Bhandoola A, Laufer TM, Burkhardt JK.

PLoS One. 2010 Aug 27;5(8):e12404. doi: 10.1371/journal.pone.0012404.

49.

Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib.

Sherrill B, Amonkar MM, Sherif B, Maltzman J, O'Rourke L, Johnston S.

Oncologist. 2010;15(9):944-53. doi: 10.1634/theoncologist.2010-0012. Epub 2010 Aug 26.

50.

Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice.

Liu X, Karnell JL, Yin B, Zhang R, Zhang J, Li P, Choi Y, Maltzman JS, Pear WS, Bassing CH, Turka LA.

J Clin Invest. 2010 Jul;120(7):2497-507. doi: 10.1172/JCI42382.

Supplemental Content

Loading ...
Support Center